In China, Drug Master Files (DMFs) are regulated by the National Medical Products Administration (NMPA). The NMPA oversees the registration, evaluation, and approval of DMFs, ensuring compliance with Chinese pharmaceutical regulations. Additionally, the Center for Drug Evaluation (CDE) under NMPA plays a crucial role in technical assessments.